» Articles » PMID: 10543757

Efficacy of Levofloxacin for Experimental Aortic-valve Endocarditis in Rabbits Infected with Viridans Group Streptococcus or Staphylococcus Aureus

Overview
Specialty Pharmacology
Date 1999 Oct 30
PMID 10543757
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Levofloxacin is among the more active fluoroquinolones against streptococci and staphylococci. It is effective against moderately severe infections caused by these organisms, but its efficacy in the treatment of bacteremia and serious infections such as endocarditis is not well defined. We compared the efficacy of levofloxacin to those of standard agents in the rabbit model of aortic-valve endocarditis caused by fluoroquinolone-susceptible strains including a penicillin-susceptible strain of Streptococcus sanguis, a penicillin-resistant strain of Streptococcus mitis, a methicillin-resistant strain of Staphylococcus aureus, and a methicillin-susceptible strain of S. aureus. Levofloxacin administered intramuscularly at dosages of 20 to 40 mg/kg of body weight twice daily (b.i.d.) was completely ineffective against the penicillin-susceptible strain, with mean vegetation titers after 3 days of therapy not statistically significantly different from those for controls. Levofloxacin was no more effective than penicillin against the penicillin-resistant strain. Levofloxacin administered for 4 days at a dosage of 20 mg/kg b.i.d. was at least as effective as vancomycin administered intravenously at a dosage of 25 mg/kg b.i. d. against the methicillin-resistant S. aureus strain and was as effective as nafcillin administered intramuscularly at 100 mg three times daily against the methicillin-susceptible strain. Emergence of resistance to levofloxacin in vitro was less likely to occur than resistance to ciprofloxacin, and resistance to levofloxacin was not observed in vivo. Levofloxacin-rifampin combinations were antagonistic in vitro and in vivo. Levofloxacin was highly effective as a single agent against experimental staphylococcal endocarditis but was surprisingly ineffective against streptococcal endocarditis, suggesting that it has a potential role as treatment for serious S. aureus but not viridans group streptococcal infections in humans.

Citing Articles

Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant : A Time-Kill Assay.

Kang Y, Chung D, Ko J, Huh K, Cho S, Kang C Antibiotics (Basel). 2023; 12(4).

PMID: 37107077 PMC: 10135007. DOI: 10.3390/antibiotics12040711.


Effectiveness of daptomycin against infective endocarditis caused by highly penicillin-resistant viridans group streptococci.

Matsuo T, Mori N, Sakurai A, Kanie T, Mikami Y, Uehara Y IDCases. 2021; 24:e01113.

PMID: 33898259 PMC: 8055607. DOI: 10.1016/j.idcr.2021.e01113.


Rifampin combination therapy for nonmycobacterial infections.

Forrest G, Tamura K Clin Microbiol Rev. 2010; 23(1):14-34.

PMID: 20065324 PMC: 2806656. DOI: 10.1128/CMR.00034-09.


Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Murillo O, Pachon M, Euba G, Verdaguer R, Tubau F, Cabellos C Antimicrob Agents Chemother. 2008; 52(10):3681-6.

PMID: 18676888 PMC: 2565888. DOI: 10.1128/AAC.00458-08.


Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.

Anguita-Alonso P, Rouse M, Piper K, Steckelberg J, Patel R Antimicrob Agents Chemother. 2006; 50(4):1263-7.

PMID: 16569838 PMC: 1426944. DOI: 10.1128/AAC.50.4.1263-1267.2006.


References
1.
Kimbrough 3rd R, Gerecht W, Husted F, WOLFE J . The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis. Mo Med. 1991; 88(9):635-7. View

2.
Nicodemo A, Robledo J, Jasovich A, Neto W . A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract. 1998; 52(2):69-74. View

3.
Brandt C, Rouse M, Tallan B, Wilson W, Steckelberg J . Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus. Antimicrob Agents Chemother. 1994; 38(9):2191-3. PMC: 284709. DOI: 10.1128/AAC.38.9.2191. View

4.
Kang S, Rybak M, McGRATH B, Kaatz G, Seo S . Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother. 1994; 38(12):2702-9. PMC: 188273. DOI: 10.1128/AAC.38.12.2702. View

5.
Greenberg R, Kennedy D, Reilly P, Luppen K, Weinandt W, Bollinger M . Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother. 1987; 31(2):151-5. PMC: 174681. DOI: 10.1128/AAC.31.2.151. View